|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Davidoff AJ, Tang M, Seal B and Edelman
MJ: Chemotherapy and survival benefit in elderly patients with
advanced non-small-cell lung cancer. J Clin Oncol. 28:2191–2197.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
5
|
Bautch VL: Cancer: Tumour stem cells
switch sides. Nature. 468:770–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wicha MS, Liu S and Dontu G: Cancer stem
cells: an old idea - a paradigm shift. Cancer Res. 66:1883–1890;
discussion 1895–1896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
8
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh SK, Clarke ID, Terasaki M, et al:
Identification of a cancer stem cell in human brain tumors. Cancer
Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
11
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eramo A, Lotti F, Sette G, et al:
Identification and expansion of the tumorigenic lung cancer stem
cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galli R, Binda E, Orfanelli U, et al:
Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tirino V, Camerlingo R, Franco R, et al:
The role of CD133 in the identification and characterisation of
tumour-initiating cells in non-small-cell lung cancer. Eur J
Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang F, Qiu Q, Khanna A, et al: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hirschmann-Jax C, Foster AE, Wulf GG, et
al: A distinct ‘side population’ of cells with high drug efflux
capacity in human tumor cells. Proc Natl Acad Sci USA.
101:14228–14233. 2004.
|
|
19
|
Meng X, Li M, Wang X, Wang Y and Ma D:
Both CD133+ and CD133− subpopulations of A549
and H446 cells contain cancer-initiating cells. Cancer Sci.
100:1040–1046. 2009.
|
|
20
|
Rege TA and Hagood JS: Thy-1 as a
regulator of cell-cell and cell-matrix interactions in axon
regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
FASEB J. 20:1045–1054. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho RW, Wang X, Diehn M, et al: Isolation
and molecular characterization of cancer stem cells in MMTV-Wnt-1
murine breast tumors. Stem Cells. 26:364–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He J, Liu Y, Zhu T, et al: CD90 is
identified as a candidate marker for cancer stem cells in primary
high-grade gliomas using tissue microarrays. Mol Cell Proteomics.
11:M111.0107442012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang ZF, Ho DW, Ng MN, et al: Significance
of CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008.
|
|
24
|
Yan YP, Luo H and Zhou XD: Isolation and
identification of lung cancer stem like cells from human lung
cancer cell line A549. J Third Mil Med Univ. 34:1153–1157.
2012.
|
|
25
|
Liu ZZ, Chen P, Lu ZD, Cui SD and Dong ZM:
Enrichment of breast cancer stem cells using a keratinocyte
serum-free medium. Chin Med J (Engl). 124:2934–2936.
2011.PubMed/NCBI
|
|
26
|
Hong X, Chedid K and Kalkanis SN:
Glioblastoma cell line-derived spheres in serum-containing medium
versus serum-free medium: a comparison of cancer stem cell
properties. Int J Oncol. 41:1693–1700. 2012.PubMed/NCBI
|
|
27
|
Chase LG, Lakshmipathy U, Solchaga LA, Rao
MS and Vemuri MC: A novel serum-free medium for the expansion of
human mesenchymal stem cells. Stem Cell Res Ther. 1:82010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiang R, Liao D, Cheng T, et al:
Downregulation of transcription factor SOX2 in cancer stem cells
suppresses growth and metastasis of lung cancer. Br J Cancer.
104:1410–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen YC, Hsu HS, Chen YW, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huss WJ, Gray DR, Greenberg NM, Mohler JL
and Smith GJ: Breast cancer resistance protein-mediated efflux of
androgen in putative benign and malignant prostate stem cells.
Cancer Res. 65:6640–6650. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Q, Shi S, Yen Y, Brown J, Ta JQ and
Le AD: A subpopulation of CD133(+) cancer stem-like cells
characterized in human oral squamous cell carcinoma confer
resistance to chemotherapy. Cancer Lett. 289:151–160. 2010.
|
|
33
|
Li HZ, Yi TB and Wu ZY: Suspension culture
combined with anticancer regimens for screening breast cancer stem
cells. Med Hypotheses. 68:988–990. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hermann PC, Huber SL, Herrler T, et al:
Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell.
1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006.
|
|
37
|
Bruno S, Bussolati B, Grange C, et al:
CD133+ renal progenitor cells contribute to tumor
angiogenesis. Am J Pathol. 169:2223–2235. 2006.
|
|
38
|
Shmelkov SV, Butler JM, Hooper AT, et al:
CD133 expression is not restricted to stem cells, and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
39
|
Wang J, Sakariassen PO, Tsinkalovsky O, et
al: CD133 negative glioma cells form tumors in nude rats and give
rise to CD133 positive cells. Int J Cancer. 122:761–768. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Joo KM, Kim SY, Jin X, et al: Clinical and
biological implications of CD133-positive and CD133-negative cells
in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
|
